Curing Cardiac Arrhythmias
2
Innovative nano-bio-medical delivery platformFirst class multidisciplinary teamPhysiological solution for curing atrial fibrillation
Becoming the world leader in magnetic targeted delivery of nanomedicines
3
Impact of Atrial Fibrillation
Most common cardiac arrhythmia worldwide
5 Million office visits/yr
Significantly increased risk of stroke
4
Novel Therapy for Atrial Fibrillation
Target neural ganglia Electromagnetic force directs nanoparticlesCurative targeted therapyVery low medical riskHighly efficient procedure
5
The Products
Magnetic Workstation
Electromagnet
X-Y-Z table
6
The Products
Nanoformulation Kit
Superparamagnetic particles
Neurotoxin therapeutic agent
Biocompatible polymer (PLGA)
7
Market Size
2.5 million patients, 2011
No. of patients estimated to triple by 2016
$16 B annual costs related to AF
8
Competition
Medication
3M
AbbottSanofi
Catheter Ablation
Medtronic
Boston Scientific
J&J
Bard
9
Revenue Model & Product Pricing
• Selling a Magnetic Work Station ~$100,000 per station
• Selling magnetic nanoparticles Nanoformulation Kit for each procedure ~$800 per procedure
Main revenue generator will be the Nano-formulation Kit for each procedure
10
Customer Acquisition Plan
• In-house marketing and sales personal to establish initial sales
• Addressing opinion leaders to get recognition and exposure
• Forming cooperative agreements with market leaders to increase sales
• Launching product in Europe followed by USA
11
Timeline
2016 -20172013 2013-2014 2014-20152012-2013
Animal StudiesInitial Clinical Trial - CE
PMA Submission
CE application
Multi Site Clinical Trials
Proof of ConceptPatent Applications Animal
StudiesDeveloping Prototype
In Progress
Initial Sales
12
The Team• Alex Harel – President & CEO – Founding and managing several
start-up companies in Israel, including BBMS Ltd.• Kenneth J. Dormer, MS, PhD – Chairman of Advisory Board - Professor of
Physiology, Senior Scientist Heart Rhythm Institute, OUHSC. • Sunny Po, MD, PhD – Primary Medical Investigator; Member of Advisory
Board - Director of Clinical Electrophysiology, Associate Director, Heart Rhythm Institute, OUHSC.
• Benjamin J. Scherlag, PhD – Investigator ; Member of Advisory Board - Regents Professor of Medicine/Cardiology, George Lynn Cross Professor of Research, OUHSC.
• Dr. Udi Katznelson, PhD– Investigator - Ph.D. in Physics, Tel-Aviv University; inventor and the designer of many magnetic and MRI products.
Collaborations:OUHSC, UT - Arlington, UOM, OSU, Center for Integrated Nanotechnologies - Sandia National Laboratories, Albuquerque, NM
13
Becoming the world leader in magnetic targeted delivery of nanomedicines
Alex Harel - CEO Ken Dormer – Chief ScientistCell: 405-445 7888 Cell: 405-706 3711 [email protected] [email protected]
Stroke-Prone, Debilitating Arrhythmia
Current Treatments Costly, Risky, Limited
Innovative, Safer, Economical, Curative
Targeted Therapy
Top Related